Literature DB >> 11731394

Science, medicine, and the future: Cellular immunotherapy for cancer.

A C Armstrong1, D Eaton, J C Ewing.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11731394      PMCID： PMC1121751          DOI： 10.1136/bmj.323.7324.1289

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  16 in total

1.  Adjuvant therapy of renal cell carcinoma with active-specific-immunotherapy (ASI) using autologous tumor vaccine.

Authors:  R Repmann; S Wagner; A Richter
Journal:  Anticancer Res       Date:  1997 Jul-Aug       Impact factor: 2.480

2.  Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer.

Authors:  J W Simons; E M Jaffee; C E Weber; H I Levitsky; W G Nelson; M A Carducci; A J Lazenby; L K Cohen; C C Finn; S M Clift; K M Hauda; L A Beck; K M Leiferman; A H Owens; S Piantadosi; G Dranoff; R C Mulligan; D M Pardoll; F F Marshall
Journal:  Cancer Res       Date:  1997-04-15       Impact factor: 12.701

3.  Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens.

Authors:  T Mutis; R Verdijk; E Schrama; B Esendam; A Brand; E Goulmy
Journal:  Blood       Date:  1999-04-01       Impact factor: 22.113

4.  Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma.

Authors:  D L Morton; D S Hoon; J A Nizze; L J Foshag; E Famatiga; L A Wanek; C Chang; R F Irie; R K Gupta; R Elashoff
Journal:  Ann N Y Acad Sci       Date:  1993-08-12       Impact factor: 5.691

5.  Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma.

Authors:  R A Figlin; J A Thompson; R M Bukowski; N J Vogelzang; A C Novick; P Lange; G D Steinberg; A S Belldegrun
Journal:  J Clin Oncol       Date:  1999-08       Impact factor: 44.544

6.  Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.

Authors:  R Childs; A Chernoff; N Contentin; E Bahceci; D Schrump; S Leitman; E J Read; J Tisdale; C Dunbar; W M Linehan; N S Young; A J Barrett
Journal:  N Engl J Med       Date:  2000-09-14       Impact factor: 91.245

7.  Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.

Authors:  S A Rosenberg; D E White
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1996-01

8.  Aldesleukin (recombinant interleukin-2): a review of its pharmacological properties, clinical efficacy and tolerability in patients with renal cell carcinoma.

Authors:  W Jeal; K L Goa
Journal:  BioDrugs       Date:  1997-04       Impact factor: 5.807

9.  Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial.

Authors:  J B Vermorken; A M Claessen; H van Tinteren; H E Gall; R Ezinga; S Meijer; R J Scheper; C J Meijer; E Bloemena; J H Ransom; M G Hanna; H M Pinedo
Journal:  Lancet       Date:  1999-01-30       Impact factor: 79.321

10.  HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia.

Authors:  C Bonini; G Ferrari; S Verzeletti; P Servida; E Zappone; L Ruggieri; M Ponzoni; S Rossini; F Mavilio; C Traversari; C Bordignon
Journal:  Science       Date:  1997-06-13       Impact factor: 47.728
View more
  8 in total

1.  Low-Frequency Sonophoresis of Chinese Medicine Formula Improves Efficacy of Malignant Pleural Effusion Treatment.

Authors:  Ai-Ping Tian; Yu-Kun Yin; Lei Yu; Bo-Yan Yang; Ning Li; Jian-Ying Li; Zhi-Min Bian; Shang-Ying Hu; Chun-Xiao Weng; Li Feng
Journal:  Chin J Integr Med       Date:  2019-08-24       Impact factor: 1.978

Review 2.  Gene therapy for cancer treatment: past, present and future.

Authors:  Deanna Cross; James K Burmester
Journal:  Clin Med Res       Date:  2006-09

3.  Trends in cancer immunotherapy.

Authors:  Joseph F Murphy
Journal:  Clin Med Insights Oncol       Date:  2010-07-14

4.  Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers.

Authors:  Vincenzo Bronte; Tihana Kasic; Giorgia Gri; Keti Gallana; Giovanna Borsellino; Ilaria Marigo; Luca Battistini; Massimo Iafrate; Tommaso Prayer-Galetti; Francesco Pagano; Antonella Viola
Journal:  J Exp Med       Date:  2005-04-11       Impact factor: 14.307

Review 5.  Cellular immunotherapies for cancer.

Authors:  Conall Hayes
Journal:  Ir J Med Sci       Date:  2020-07-01       Impact factor: 1.568

6.  Assessment of the Anti-Cancer Efficiency of Silver Moringa oleifera Leaves Nano-extract against Colon Cancer Induced Chemically in Rats.

Authors:  Wael Mahmoud Aboulthana; Wafaa Ghoneim Shousha; Ehab Abdel-Raouf Essawy; Mahmoud Hosny Saleh; Alaa Hamed Salama
Journal:  Asian Pac J Cancer Prev       Date:  2021-10-01

7.  Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact.

Authors:  G Alì; L Boldrini; M Lucchi; A Picchi; M Dell'Omodarme; M C Prati; A Mussi; V Corsi; G Fontanini
Journal:  Br J Cancer       Date:  2009-12-01       Impact factor: 7.640

Review 8.  Adoptive cellular immunotherapy in metastatic renal cell carcinoma: a systematic review and meta-analysis.

Authors:  Xiaoyi Tang; Ting Liu; Xuefeng Zang; Hao Liu; Danhong Wang; Hu Chen; Bin Zhang
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.